XNCR News and Press, Xencor Inc. From 09/20/19

School is back in session, football season is under way, and the post-Labor Day IPO market has provided new investment opportunities, with some shining stocks debuting in the healthcare sector.  Last week, three healthcare companies completed their IPOs: 10X Genomics (NASDAQ: TXG) , ...

Quick Take IGM Biosciences ( IGMS ) intends to raise $125 million from the sale of its common stock in an IPO, per an S-1/A registration statement . The company is developing a pipeline of antibodies for the treatment of various blood cancers. IGMS is still in pre-Phase 1 safety trial s...

Sophisticated pharma investors will need to review the IGM Biosciences ( IGMS )' preclinical data. Janus Capital Management acquired shares, and the company holds a significant amount of cash. It means that preclinical research impressed institutional investors and may impress others. Having s...

Quick Take IGM Biosciences ( IGMS ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the development of engineered IgM antibodies as cancer treatments. IGMS is a very early stage firm seeking public ca...

Neurocrine Biosciences (NASDAQ: NBIX ) initiated with Outperform rating and $118 (24% upside) price target at RBC. More news on: Neurocrine Biosciences, Inc., Regeneron Pharmaceuticals, Inc., Allergan plc, Healthcare stocks news, Stocks on the move, , Read more ...

Xencor, Inc. (XNCR) Q2 2019 Results Earnings Conference Call August 06, 2019, 04:30 PM ET Company Participants Charles Liles - Associate Director & Head of Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer Paul Foster -...

Xencor (NASDAQ: XNCR ): Q2 GAAP EPS of -$0.28 beats by $0.17 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Management to Host Conference Call at 4:30 p.m. ET today -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today reported financial resu...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release second quarter 2019 financial results after the market close...

Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...